Acquired hemophilia in pediatrics: a systematic review
- PMID: 20589621
- DOI: 10.1002/pbc.22657
Acquired hemophilia in pediatrics: a systematic review
Abstract
Acquired hemophilia A is a rare but potentially life-threatening hemorrhagic disorder caused by the development of autoantibodies directed mostly against coagulation factor VIII. Acquired hemophilia is frequently associated with several underlying conditions such as malignancy, autoimmune disorders, drug reactions, and pregnancy, although the pathogenesis remains undetermined (idiopathic) in up to 50% of reported cases. The disorder occurs most commonly in the elderly and only rarely affects pediatric patients, who might however experience severe, and sometimes life-threatening, hemorrhage. The maternal transplacental transfer of the autoantibody to the neonate occurs very rarely and also in this circumstance it may be associated with clinically significant bleeding. The management of acute bleeding and the inhibitor eradication are the mainstay of the treatment. The outcome in pediatric patients seems more favorable than in adults because the inhibitors usually resolve more quickly and in a higher rate of patients. The epidemiology, diagnosis, clinical course, and management of this hemorrhagic disorder in children will be addressed in this systematic review.
Copyright 2010 Wiley-Liss, Inc.
Similar articles
-
Drug-induced anti-factor VIII antibodies: a systematic review.Med Sci Monit. 2007 Apr;13(4):RA55-61. Med Sci Monit. 2007. PMID: 17392659
-
Acquired factor VIII inhibitors in oncohematology: a systematic review.Crit Rev Oncol Hematol. 2008 Jun;66(3):194-9. doi: 10.1016/j.critrevonc.2007.12.004. Epub 2008 Feb 19. Crit Rev Oncol Hematol. 2008. PMID: 18243727
-
The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis.Blood Coagul Fibrinolysis. 2009 Oct;20(7):517-23. doi: 10.1097/MBC.0b013e32832ca388. Blood Coagul Fibrinolysis. 2009. PMID: 19644360
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.Cochrane Database Syst Rev. 2021 Aug 18;8(8):CD014201. doi: 10.1002/14651858.CD014201. Cochrane Database Syst Rev. 2021. PMID: 34407214 Free PMC article.
Cited by
-
Acquired Haemophilia A: A Review of What We Know.J Blood Med. 2022 Nov 23;13:691-710. doi: 10.2147/JBM.S342077. eCollection 2022. J Blood Med. 2022. PMID: 36447782 Free PMC article. Review.
-
Management of rare acquired bleeding disorders.Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):80-87. doi: 10.1182/hematology.2019000066. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808848 Free PMC article.
-
Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies.Medicina (Kaunas). 2023 Sep 28;59(10):1739. doi: 10.3390/medicina59101739. Medicina (Kaunas). 2023. PMID: 37893457 Free PMC article. Review.
-
Acquired hemophilia in a 7-year-old girl successfully treated with recombinant FVIIA and steroids: A case report.Clin Case Rep. 2020 Dec 3;9(2):638-643. doi: 10.1002/ccr3.3588. eCollection 2021 Feb. Clin Case Rep. 2020. PMID: 33598217 Free PMC article.
-
Acquired Hemophilia Associated with Rheumatoid Arthritis: A Case Report and Review of the Literature.Int J Mol Sci. 2025 Apr 11;26(8):3628. doi: 10.3390/ijms26083628. Int J Mol Sci. 2025. PMID: 40332156 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical